Company intelligence / Profile preview
Linnaeus Therapeutics
Haddonfield, New Jersey, United Stateslinnaeustx.com ↗
- Ownership
- Private
- Employees
- ~25
- Development stage
- Other
01
Overview
LNS8801, the lead candidate, is an orally bioavailable small molecule GPER agonist. In phase 1/2 trials, it has shown safety, tolerability, target engagement (GPER activation, c-Myc depletion), and preliminary clinical benefit in advanced cancer, particularly metastatic cutaneous melanoma. Orphan drug designation has been granted. A randomized pivotal trial in melanoma progressing after checkpoint inhibitors is planned.
- Therapeutic areas
- Oncology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Penn Center for Innovation UPstart (University of Pennsylvania)
Beyond the preview
Go deeper on Linnaeus Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Linnaeus Therapeutics.